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interface
Kimiko Kuroki and Katsumi Maenaka
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HLA-G is a non-classical human MHC class I molecule, which has several characteristics
distinct from classical MHC, such as low polymorphism and restricted tissue
distribution. HLA-G is expressed on placenta, thymus and some tumors. At the
maternal-fetal interface, trophoblasts do not express major classical MHC class I
molecules (MHCI), HLA-A and -B, to prevent normal Tcell responses. Instead, HLA-G is
expressed and can suppress a wide range of immune responses by binding to inhibitory
immune cell surface receptors, such as leukocyte Ig-likereceptor (LILR) B1 and LILRB2.
HLA-G existsinvariousforms,includingb2m-associatedor-free disulfide-linkeddimers
that can be expressed either at the cell surface or in soluble form. However, until
recently the physiological role of these different molecular forms has been unclear. In
this issue of the European Journal of Immunology, one article demonstrates that the
disulfide-linkedhomodimerofb2m-associatedHLA-Gisthemajorfractionexpressedby
trophoblast cells. The HLA-G dimer modulates the function of LILRB1-expressing
antigen-presenting cells by principally binding to LILRB1. On the other hand, another
recent report showed that b2m-free disulfide-linked HLA-G dimers are produced by
villous cytotrophoblast cells. Taken together, these results provide strong evidence in
support of the hypothesis that HLA-G dimers play a role in immune suppression at the
maternal-fetal interface. Further in-depth investigation will help to clarify the precise
mechanism of HLA-G receptor recognition and signaling in vivo and the role of these
interactions in successful reproduction.
See accompanying article: http://dx.doi.org/10.1002/eji.200737089
During pregnancy, the semi-allogeneic fetus needs to
avoid maternal immune responses. A specific immune
suppression system employing the non-classical MHC
class I molecule (MHCI), HLA-G [1, 2] has been adapted
for this purpose. The gene encoding HLA-G is located
within the MHC region; however, HLA-G has very low
polymorphism by contrast with the high polymorphism
of classical MHCI. Although HLA-G is expressed by
placental trophoblast cells, these cells do not express
major classical MHCI, HLA-A or -B, resulting in the
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expressed trophoblast HLA-G can suppress immune
responses by binding to inhibitory receptors. The HLA-G
receptors reported to date are the leukocyte Ig-like
receptors (LILR) B1 and B2, killer cell Ig-like receptor
(KIR) 2DL4, CD160 and CD8 [2–4] (Fig. 1). Previous
reports clearly demonstrate that LILRB1 and LILRB2
preferentially bind to HLA-G compared with other
classical MHCI [5]. Intriguingly, HLA-G is expressed in
several unusual forms in addition to the conventional
heterotrimer, associated with b2m and peptide, made by
all classical MHCI. These include: (i) a disulfide-linked
b2m-associated dimer; (ii) a b2m-free heavy chain, (iii)
its disulfide-linked dimer, and (iv) domain-deleted and
soluble splice variants [6]. Previousinvitrostudiesusing
either recombinant proteins, transfectants or cell lines
demonstrated that HLA-G can exist as a disulfide-linked
dimer of the conventional b2m-associated form (and in
some cases, trimeric and oligomeric forms) [7, 8]. In this
issue, Apps et al. [9] demonstrate that significant
amounts of the b2m-associated HLA-G dimer are
expressed at the cell surface of normal first trimester
trophoblast cells. Furthermore, they also found that
LILRB1 is the principal ligand for the HLA-G dimer.
These results are consistent with previous studies
showing that the HLA-G dimers bind with greater
avidity to LILRB1/2 and signal more strongly through
LILR than monomeric HLA-G and other classical MHCI
[10, 11] (Fig. 1). Therefore, the HLA-G dimer pre-
sumably has a significantly pivotal in vivo role in
maternal-fetal interface, in comparison with the mono-
meric form. In addition to the crystal structure of the
HLA-G monomer [12], the recent structural study [10]
showed that the disulfide-linked dimer exhibits an
oblique configuration exposing two upward facing
LILR/CD8 binding sites, readily accessible to receptors,
explaining the increased avidity. On the other hand, the
peptide-binding grooves are very close, possibly pre-
venting T cell receptor binding (Fig. 1).
There are some reports demonstrating the existence
of a b2m-free heavy chain form of HLA-G. Gonen-Gross
et al. [11] demonstrated placental expression of the
b2m-free form of HLA-G by in situ immunostaining.
Furthermore, Morales et al. [13] recently showed that
villous cytotrophoblast cells (vCTB) express the dimeric
form of b2m-free HLA-G. Based on these results, Hunt et
al. [14] summarized the expression pattern of HLA-G
variants in placenta. These results are different from
those of Apps et al. [9] with regards to the b2m
association of HLA-G dimer in placenta, and might be a
consequence of the different cell populations used in
each study. Recent reports [11, 15] have shown that
LILRB2 can recognize the b2m-free MHCI, but LILRB1
cannot (Fig. 1). Therefore, b2m-free HLA-G confers an
inhibitory effect selectively on LILRB2-expressing cells,
such as antigen-presenting cells (APC). Furthermore,
Kollnberger et al. [16] showed that b2m-free HLA-B27
dimer binds to KIR3DL2 and KIR3DL1 as well as LILRB2.
Thus, it will be of great interest to see whether b2m-free
HLA-G dimer binds to LILRB and KIR with greater
avidity than monomer.
Emerging studies have revealed the potential roles of
various forms of MHCI, including b2m-free MHCI (and
its homodimer) and associated forms with other
unrelated molecules [17]. As described above, HLA-G
can exist in similar forms, but possesses unique cysteine
residues distinct from other MHCI, including Cys42,
which is involved in disulfide-linked dimer formation
without any conformational changes. Therefore, both
b2m-associated and -free forms of the HLA-G dimer
could have distinct roles in immune suppression from
those of normal MHCI.
Thesoluble formofHLA-G(sHLA-G)issecretedand/
or shed from the cell surface toward the decidua area.
sHLA-G can inhibit immune responses of LILRB1/2-
expressing cells in the decidua and can also interact with
Figure 1. Receptor recognition of the different forms of HLA-G
at the maternal-fetal interface. HLA-G can be expressed in
various forms in placenta. The structures of b2m-associated
HLA-G monomer and dimer are shown. LILRB1 (light blue),
which is expressed on decidual antigen-presenting cells (APC)
and subsets of NK and T cells, binds to only b2m-associated
formsofHLA-Gmonomeranddimer.LILRB2(darkblue),whose
expression is restricted to decidual APC, binds to both b2m-
associated and -free forms of HLA-G monomer and dimer.
LILRB1 and LILRB2 presumably bind to HLA-G dimer more
strongly than its monomer. The thickness of the arrows
correspondstothesignalstrength.Bothmembrane-boundand
soluble forms likely inhibit the immune responses of LILRB-
expressing cells. On the other hand, the HLA-G recognition of
CD160 and KIR2DL4 still remains unclear.
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possibly resulting in the anti-angiogenic effects on
uterine vascular remodeling in pregnancy. By contrast,
sHLA-G binds to KIR2DL4 at the cell surface and is
internalized into endosomes, whereas the membrane-
bound form of HLA-G cannot, thus stimulating pro-
inflammatory and pro-angiogenic cytokines production,
which would be helpful inincreasing blood supplytothe
placenta [19]. Using a killing assay, Yan et al. [20]
revealed that the KIR2DL4 binding site is located in the
C-terminal peptide-binding site of the HLA-G a1 helix.
This suggests that the HLA-G dimer may not be able to
bind to KIR2DL4 because of the close proximity of the
peptide-binding grooves. However, without further
biochemical evidence it is not possible to draw any
definitive conclusions. Further in-depth investigations,
especially comprehensive binding studies with recom-
binant proteins, will clarify the precise role of HLA-G
monomer and dimer interactions with KIR2DL4 and
CD160 in immune regulation.
Taken together, the current evidence and the results
from Apps et al. [9] strongly suggest that LILR
recognition of HLA-G dimers has a pivotal role to play
in immune suppression at the maternal-fetal interface,
possibly contributing to the prevention of pregnancy
complications such as pre-eclampsia and recurrent
abortion. Further detailed analysis of the interaction
of HLA-G with LILR and KIR families, CD160 and maybe
as yet-unidentified receptors will provide a clear
molecular basis of how these interactions may be
involved in immune suppression and the control of
angiogenesis in vivo. These studies may also provide
future avenues of research with potential clinical
applications.
Acknowledgements: This work was supported in part
by the New Energy and Industrial Technology Devel-
opment Organization (NEDO) of Japan, Ministry of
Education, Science, Sports, Culture and Technology of
Japan, and the Japan Bio-oriented Technology Research
Advancement Institute (BRAIN).
References
1 Geraghty, D. E., Koller, B. H. and Orr, H. T., A human major
histocompatibility complex class I gene that encodes a protein with a
shortened cytoplasmic segment. Proc. Natl. Acad. Sci. USA 1987. 84:
9145–9149.
2 Hunt, J. S., Petroff, M. G., McIntire, R. H. and Ober, C., HLA-G and
immune tolerance in pregnancy. FASEB J. 2005. 19: 681–693.
3 Colonna, M., Nakajima, H. and Cella, M., Inhibitory and activating
receptors involved in immune surveillance by human NK and myeloid cells.
J. Leukoc. Biol. 1999. 66: 718–722.
4 O'Callaghan, C.A.andBell, J. I.,Structureand function of thehumanMHC
class Ib molecules HLA-E, HLA-F and HLA-G. Immunol. Rev. 1998. 163:
129–138.
5 Shiroishi, M., Tsumoto, K., Amano, K., Shirakihara, Y., Colonna, M.,
Braud, V. M., Allan, D. S. et al., Human inhibitory receptors Ig-like
transcript 2 (ILT2) and ILT4 compete with CD8 for MHC class I binding and
bind preferentially to HLA-G. Proc. Natl. Acad. Sci. USA 2003. 100:
8856–8861.
6 Ishitani, A. and Geraghty, D. E., Alternative splicing of HLA-G transcripts
yields proteins with primary structures resembling both class I and class II
antigens. Proc. Natl. Acad. Sci. USA 1992. 89: 3947–3951.
7 Gonen-Gross, T., Achdout, H., Gazit, R., Hanna, J., Mizrahi, S., Markel,
G., Goldman-Wohl, D. et al., Complexes of HLA-G protein on the cell
surface are important for leukocyte Ig-like receptor-1 function. J. Immunol.
2003. 171: 1343–1351.
8 Boyson, J. E., Erskine, R., Whitman, M. C., Chiu, M., Lau, J. M.,
Koopman, L. A., Valter, M. M. et al., Disulfide bond-mediated dimerization
of HLA-G on the cell surface. Proc. Natl. Acad. Sci. USA 2002. 99:
16180–16185.
9 Apps, R., Gardner, L., Sharkey, A. M., Holmes, N. and Moffett, A., A
homodimeric complex of HLA G on normal trophoblast modulates antigen-
presenting cells via LILRB1. Eur. J. Immunol. 2007. 37: DOI10.1002/
eji.200737089.
10 Shiroishi, M., Kuroki, K., Ose, T., Rasubala, L., Shiratori, I., Arase, H.,
Tsumoto, K. et al., Efficient leukocyte Ig-like receptor signaling and crystal
structure of disulfide-linked HLA-G dimer. J. Biol. Chem. 2006. 281:
10439–10447.
11 Gonen-Gross, T., Achdout, H., Arnon, T. I., Gazit, R., Stern, N., Horejsi,
V., Goldman-Wohl, D. et al., The CD85J/leukocyte inhibitory receptor-1
distinguishes between conformed and beta2-microglobulin-free HLA-G
molecules. J. Immunol. 2005. 175: 4866–4874.
12 Clements,C.S.,Kjer-Nielsen,L.,Kostenko,L.,Hoare,H. L.,Dunstone, M.
A., Moses, E., Freed, K. et al., Crystal structure of HLA-G: a nonclassical
MHC class I molecule expressed at the fetal-maternal interface. Proc. Natl.
Acad. Sci. USA 2005. 102: 3360–3365.
13 Morales, P. J., Pace, J. L., Platt, J. S., Langat, D. K. and Hunt, J. S.,
Synthesis of beta(2)-microglobulin-free, disulphide-linked HLA-G5 homo-
dimers in human placental villous cytotrophoblast cells. Immunology 2007,
in press.
14 Hunt, J. S., Morales, P. J., Pace, J. L., Fazleabas, A. T. and Langat, D. K., A
commentary on gestational programming and functions of HLA-G in
pregnancy. Placenta 2007. 28 Suppl A: S57–63.
15 Shiroishi, M., Kuroki, K., Rasubala, L., Tsumoto, K., Kumagai, I.,
Kurimoto, E., Kato, K. et al., Structural basis for recognition of the
nonclassical MHC molecule HLA-G by the leukocyte Ig-like receptor B2
(LILRB2/LIR2/ILT4/CD85d). Proc. Natl. Acad. Sci. USA 2006. 103:
16412–16417.
16 Kollnberger,S., Chan, A.,Sun, M.Y., YeChen, L., Wright,C.,di Gleria, K.,
McMichael, A. and Bowness, P., Interaction of HLA-B27 homodimers with
KIR3DL1andKIR3DL2,unlikeHLA-B27heterotrimers,isindependentof the
sequence of bound peptide. Eur. J. Immunol. 2007. 37: 1313–1322.
17 Arosa, F. A., Santos, S. G. and Powis, S. J., Open conformers: the hidden
face of MHC-I molecules. Trends Immunol. 2007. 28: 115–123.
18 Le Bouteiller, P., Fons, P., Herault, J. P., Bono, F., Chabot, S., Cartwright,
J. E. and Bensussan, A., Soluble HLA-G and control of angiogenesis. J.
Reprod. Immunol. 2007, in press.
19 Rajagopalan, S., Bryceson, Y. T., Kuppusamy, S. P., Geraghty, D. E., van
der Meer, A., Joosten, I. and Long, E. O., Activation of NK cells by an
endocytosed receptor for soluble HLA-G. PLoS Biol. 2006. 4: e9.
20 Yan, W. H. and Fan, L. A., Residues Met76 and Gln79 in HLA-G alpha1
domain involve in KIR2DL4 recognition. Cell Res. 2005. 15: 176–182.
Eur. J. Immunol. 2007. 37: 1727–1729 Highlights 1729
f 2007 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim www.eji-journal.eu